ea0077pl5 | Society for Endocrinology International Medal Lecture | SFEBES2021
Febbraio Mark
The gp130 receptor (gp130R) cytokines interleukin-6 (IL-6) and ciliary neurotrophic factor (CNTF) can improve metabolic disease, but due to the known pro-inflammatory effects of IL-6 and the antigenic response to the clinically used form of CNTF (AxokineTM), both proteins have limited therapeutic utility. Accordingly, we recently engineered a chimeric gp130R ligand, termed IC7Fc, where one gp130 binding site has been removed from IL-6 and replaced with the leukemia ...